The impending loss of exclusivity for Eliquis (apixaban) is poised to become one of the most significant revenue-generating events in pharmaceutical history, with projected losses of $14.2 billion over six years. This stark forecast illustrates the dramatic impact that generic competition can have on even the most dominant and entrenched blockbuster drugs, underscoring a critical challenge facing the pharmaceutical industry today: the rapid erosion of value once patent protections expire.
Eliquis, a flagship product jointly developed and marketed by Bristol Myers Squibb (BMS) and Pfizer, has achieved remarkable commercial success as a leading oral anticoagulant. Its widespread clinical adoption and extensive prescriber base have cemented its position as a dominant force in the global market for preventing strokes and treating venous thromboembolic conditions. However, the approaching patent expirations in key markets, beginning in Europe this year and followed by the United States and Japan in 2027, signal a profound shift in its commercial trajectory. The drug’s considerable market share, reflected in global sales that reached an impressive $14.4 billion in 2025, makes its upcoming patent cliff a focal point for financial analysts, industry executives, and healthcare stakeholders.
A Chronicle of Dominance and Decline
Approved initially in the European Union in May 2011 and subsequently by the U.S. Food and Drug Administration (FDA) in December 2012, Eliquis quickly established itself as a cornerstone therapy. As a direct factor Xa inhibitor, it offers a compelling alternative to older anticoagulants, particularly for patients with non-valvular atrial fibrillation and those recovering from deep vein thrombosis or pulmonary embolism. Its efficacy, safety profile, and convenient oral administration have contributed to its broad market penetration and significant revenue generation for its developers.
The anticipated revenue trajectory for Eliquis paints a dramatic picture of market disruption. Projections indicate a precipitous fall in global sales from approximately $14.4 billion in 2025 to a mere $205 million by 2031. This represents a near-total revenue erosion of 98.6%, positioning this loss-of-exclusivity (LOE) event as one of the most substantial single-asset declines in the pharmaceutical sector’s recent memory. This decline is not a uniform, gradual fade but rather a geographically sequenced implosion, driven by distinct market dynamics and regulatory timelines.
The initial wave of revenue compression is set to begin with the lapse of European exclusivity in May 2026. This event will trigger a significant downturn in sales across ex-European markets. Following this, the United States market, which currently represents the largest portion of Eliquis’s revenue, will experience its own dramatic cliff in 2028. This latter event is expected to drive the steepest absolute destruction of revenue, culminating in the overall projected $14.2 billion loss over the six-year period.
Navigating the Geographic Sequels of Exclusivity Loss
The impact of Eliquis’s patent expiry will unfold in distinct phases across different global regions, each with its own set of market pressures. In the period immediately following the European patent lapse, revenues from markets outside the U.S. are forecast to experience a sharp decline of nearly 75% between 2025 and 2027. This rapid erosion in these regions is largely attributable to the swift adoption of generic alternatives, facilitated by established tendering systems and formulary-level switches that can displace branded medications with remarkable speed once exclusivity ceases.
In contrast, the U.S. market is anticipated to remain relatively insulated from the initial wave of generic competition. During this period, the U.S. share of Eliquis’s total portfolio revenue is projected to surge, potentially reaching close to 90% by 2027. This concentration of revenue in the U.S. reflects the drug’s continued strong performance in its largest and most lucrative market, even as European and other international markets begin to transition. However, this period of relative stability is a temporary reprieve before the significant U.S. patent cliff.
The U.S. market’s experience with revenue decline is also influenced by regulatory developments preceding the actual patent expiry. The Inflation Reduction Act (IRA), enacted in the United States, mandates Medicare maximum fair prices for selected high-cost drugs. For Eliquis, a maximum fair price of $231 per 30-day supply took effect in January 2026. This measure began to exert downward pressure on net revenues two years before the primary patent cliff, effectively initiating a reduction in income even before generic entry was permitted.
When U.S. exclusivity ultimately expires in 2028, the impact is projected to be immediate and severe. A nearly 50% single-year decline in U.S. revenues is anticipated, driven by the characteristic rapid generic substitution dynamics of the American pharmaceutical market. In the U.S., formulary switches and substitution-at-dispensing practices can lead to a swift reallocation of market share within mere quarters of a generic product’s launch. By 2031, U.S. revenues are expected to have plummeted by 99% from their 2025 peak, contributing over $10 billion to the total projected revenue losses during the forecast period.
Strategic Realignments in the Face of the Cliff
The impending loss of Eliquis’s market exclusivity is not merely an event to be weathered but a catalyst for profound strategic repositioning within Bristol Myers Squibb. The long-anticipated nature of this LOE event has allowed the company to prepare for the inevitable revenue decline. The critical intelligence for the industry lies not in the LOE date itself, which has been factored into market expectations for some time, but in the velocity and magnitude of the post-exclusivity revenue compression observed across sequential geographies.
In response to this predictable commercial challenge, BMS has embarked on a significant capital allocation strategy focused on diversification and the acquisition of future growth engines. The company has made substantial investments, including the $14 billion acquisition of Karuna Therapeutics and the $4.1 billion acquisition of RayzeBio. These strategic moves represent deliberate bets on emerging therapeutic areas, specifically neuroscience and radiopharmaceuticals, as potential replacement growth platforms to offset the impending erosion of Eliquis revenue.
The acquisition of Karuna Therapeutics has already yielded tangible results. Its lead asset, Cobenfy (formerly KarXT), received FDA approval in September 2024. This approval marked a significant milestone as it represented the first new class of schizophrenia treatment to be authorized in over 50 years. Cobenfy commenced its commercial launch in the U.S. in late 2024, signaling that BMS’s merger-and-acquisition-led repositioning strategy is beginning to demonstrate its potential to generate new revenue streams. This development is particularly timely, occurring ahead of the most intense phase of Eliquis’s revenue decline.
Broader Implications for the Pharmaceutical Landscape
As one of the largest cardiovascular brands currently approaching the end of its patent protection, Eliquis’s trajectory will serve as a crucial benchmark for the industry. Its performance will offer vital insights into the speed at which revenues can diminish once major global markets transition to generic alternatives. The projected fall from approximately $14.4 billion in peak annual sales to well below $1 billion within a roughly five-year timeframe powerfully illustrates a central theme in contemporary pharmaceutical business strategy: an over-reliance on a single, high-performing asset exposes large pharmaceutical companies to rapid and substantial value erosion.
This scenario underscores the critical imperative for early and effective diversification. For major pharmaceutical players, proactive strategies to build and launch new revenue streams ahead of significant LOE events are no longer optional but an essential component of long-term financial health and sustainability. The Eliquis LOE event is a potent reminder that even the most successful brands are subject to the relentless cycle of innovation and competition, necessitating a constant evolution of product portfolios and strategic foresight.
The financial implications for both Bristol Myers Squibb and Pfizer are substantial. While both companies have diversified portfolios, Eliquis has been a major contributor to their top-line growth. The revenue gap left by its genericization will require significant contributions from other pipeline assets and existing products to maintain overall company performance. Analysts will be closely monitoring the success of BMS’s recent acquisitions and Pfizer’s own strategic initiatives in filling this void.
Furthermore, the Eliquis case highlights the ongoing impact of regulatory policies on drug pricing and market dynamics. The IRA’s price negotiation provisions, while intended to reduce healthcare costs, demonstrate how legislative actions can directly influence revenue streams for pharmaceutical companies, even before patent expiries. This adds another layer of complexity to long-term financial planning and revenue forecasting within the industry.
The widespread availability of generic apixaban is also expected to lead to significant cost savings for healthcare systems and patients globally. Lower-priced alternatives will increase patient access to essential anticoagulant therapy, a positive outcome for public health. However, for the pharmaceutical companies that invested heavily in the research, development, and marketing of Eliquis, the challenge of replacing lost revenue remains a paramount concern, driving ongoing innovation and strategic adaptation within the sector. The story of Eliquis’s impending LOE is thus a multifaceted narrative of scientific achievement, commercial success, market forces, and the strategic imperatives that shape the future of the pharmaceutical industry.
Leave a Reply